Formulation challenges for enhancing the bioavailability of poorly soluble API’s can be solved by spray drying. Thermo Fisher’s Pharma Services is on track for operational availability of their Florence (East), South Carolina, commercial spray drying facility in July 2019.
When developing new pharmaceutical products, it is very important to get to the Phase I clinical trial in a fast, efficient and cost-effective way. With its oral solid dose Quick-to-Clinic™ program, Thermo Fisher Scientific can deliver a prospective drug in a phase-appropriate formulation for first-in-human studies in as little as 14 weeks.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that it has completed its previously announced acquisition of Brammer Bio, a leader in viral vector manufacturing for gene and cell therapies, for approximately $1.7 billion in cash. The completion of the transaction follows the receipt of all required regulatory approvals.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that it has entered into a definitive agreement to acquire a drug substance manufacturing site in Cork, Ireland, from GlaxoSmithKline plc (NYSE: GSK) for approximately €90 million in cash. The Cork site will expand capacity to meet customer demand for the development and commercial manufacturing of complex active pharmaceutical ingredients (APIs).